

In re application of:

Serial No.: 09/442,256

Filed: November 17, 1999

For: **ANTI-CANCER PHARMACEUTICAL COMPOSITIONS AND METHODS**

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith is a Response to Restriction and Election Requirement in the above-identified application.

- ☐ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- ☐ Petition for Extension of Time
- ☐ No additional fee is required.

The fee has been calculated as shown below:

| | (Col. 1) | | (Col. 2) | (Col. 3) |
|--|---|-------|---------------------------------------|------------------|
| | CLAIMS REMAINING AFTER AMENDMENT | | HIGHEST NO. PREVIOUSLY PAID FOR | PRESENT EXTRA |
| TOTAL | * 53 | MINUS | ** 53 | = 0 |
| INDEP | * 3 | MINUS | *** 3 | = 0 |
| FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM | | | | |

| SMALL ENTITY | |
|--------------------|---------------|
| RATE | ADDIT. FEE |
| x 9 = | \$0 |
| x 39 = | \$0 |
| +130 = | \$ |
| TOTAL ADDIT FEE | \$0 |

| OTHER THAN A SMALL ENTITY | |
|------------------------------|---------------|
| RATE | ADDIT. FEE |
| x18 = | \$ 0 |
| x78 = | \$ 0 |
| +260 = | \$ 0 |
| or TOTAL ADDIT. FEE | \$ 0 |

* If the entry in Col.1 is less than the entry in Col.2, write "0" in Col.3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the number found from the equivalent box in Col.1 of a prior amendment the number of claims originally filed.

- ☐ Please charge my Deposit Account No. 11-0855 in the amount of \$____. A duplicate copy of this sheet is attached.
- ☐ A check in the amount of \$55 is attached.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 11-0855. A duplicate copy of this sheet is attached.
- ☒ Any filing fees under 37

CFR 1.16 for the presentation of extra claims.

- ☒ Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

Kristin D. Mallatt
Kristin D. Mallatt, Reg. No. P-46,895



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Tesfaye Zerihun
Yigzaw

SERIAL NO.: 09/442,256

GROUP ART UNIT: 1651

FILED: November 17, 1999

EXAMINER: H. Lilling

FOR: ANTI-CANCER PHARMACEUTICAL COMPOSITIONS AND METHODS

Attorney Docket No.: 38179/190315

I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope as first class addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on July 24, 2000.

Ryan L. Smith

Assistant Commissioner for
Patents
Washington, D.C. 20231

DATE: July 24, 2000

RESPONSE TO RESTRICTION AND ELECTION REQUIREMENT

Sir:

Responsive to the Office action dated May 22, 2000. Applicant respectfully submits the following remarks in connection with the above-identified application.

REMARKS

The Examiner has restricted the application between the following groups of inventions:

Group I: Claims 2-21, drawn to a composition;

Group II: Claims 22-40, drawn to a method of producing a composition;

and